Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 15/20 | 0.59 |
| ▸ | SLC5A2 | P31639 | 15/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25767433 | 0.88 | TP53 (0.67) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL2217219 | 0.82 | HTT (0.49) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL23771920 | 0.81 | NPSR1 (0.57) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL3455812 | 0.79 | NPSR1 (0.55) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL3455838 | 0.78 | ALDH1A1 (0.57) | NPSR1TP53ALOX12ALDH1A1MAPT | |
| SCHEMBL3455998 | 0.77 | NPSR1 (0.53) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL3457264 | 0.77 | CA1 (0.63) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL3455348 | 0.75 | NPSR1 (0.50) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL17321555 | 0.75 | TP53 (0.71) | SLC5A1SLC5A2NPSR1TP53ALOX12 | |
| SCHEMBL17321491 | 0.75 | MAPT (0.47) | NPSR1TP53ALOX12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | SLC5A1 2602/4885SLC5A2 3263/4885NPSR1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.